OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast Cancer

December 16th 2021

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Bestvina on the Emerging Role of Neoadjuvant Chemoimmunotherapy in Lung Cancer

December 16th 2021

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

Dr. Mark on Establishing MRD as a Surrogate Marker for Survival in Multiple Myeloma

December 16th 2021

Tomer Mark, MD, discusses establishing minimal residual disease (MRD) as a surrogate marker for survival in multiple myeloma.

Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC

December 15th 2021

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

December 15th 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

December 15th 2021

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Dr. Lazar on the Current State of Diagnosis and Treatment in Desmoid Tumors

December 15th 2021

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

Dr. Siddiqui on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

December 14th 2021

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Jain on the Need to Enroll Heterogenous Populations to Clinical Trials in CRC

December 14th 2021

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Dr. McKinney on the Emergence of CAR T-Cell Therapy in Relapsed/Refractory MCL

December 14th 2021

Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Burke on POLARIX Data Examining a Polatuzumab Vedotin–Based Regimen in Newly Diagnosed DLBCL

December 14th 2021

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma

December 14th 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Heyman on Future Therapeutic Directions in MCL

December 14th 2021

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

December 14th 2021

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

December 14th 2021

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

December 13th 2021

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Ghia on the Results From the 2-Year Follow-Up of the CAPTIVATE Study in CLL

December 13th 2021

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

December 12th 2021

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

December 12th 2021

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin Lymphoma

December 11th 2021

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.